WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2014199377) COMPOSITIONS AND METHODS FOR TREATING A HEMATOLOGICAL MALIGNANCY ASSOCIATED WITH AN ALTERED RUNX1 ACTIVITY OR EXPRESSION
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2014/199377    International Application No.:    PCT/IL2014/050523
Publication Date: 18.12.2014 International Filing Date: 10.06.2014
IPC:
A61K 31/00 (2006.01), A61P 35/02 (2006.01), A61K 38/00 (2006.01)
Applicants: YEDA RESEARCH AND DEVELOPMENT CO. LTD. [IL/IL]; at the Weizmann Institute of Science P.O. Box 95 7610002 Rehovot (IL)
Inventors: GRONER, Yoram; (IL).
BEN-AMI, Oren; (IL)
Agent: EHRLICH, Gal; G.E. Ehrlich (1995) Ltd. 11 Menachem Begin Road 5268104 Ramat Gan (IL)
Priority Data:
61/833,006 10.06.2013 US
Title (EN) COMPOSITIONS AND METHODS FOR TREATING A HEMATOLOGICAL MALIGNANCY ASSOCIATED WITH AN ALTERED RUNX1 ACTIVITY OR EXPRESSION
(FR) COMPOSITIONS ET PROCÉDÉS DE TRAITEMENT D'UNE MALIGNITÉ HÉMATOLOGIQUE ASSOCIÉE À UNE ACTIVITÉ OU UNE EXPRESSION MODIFIÉE DE RUNX1
Abstract: front page image
(EN)A method of treating a hematological malignancy associated with an altered RUNX1 activity or expression is disclosed. The method comprising administering to a subject in need thereof a therapeutically effective amount of an agent which directly downregulates an activity or expression of RUNX1, thereby treating the hematological malignancy associated with the altered RUNX1 activity or expression.
(FR)La présente invention concerne un procédé de traitement d'une malignité hématologique associée à une activité ou une expression modifiées de RUNX1. Le procédé comprend l'administration à un sujet le nécessitant d'une quantité thérapeutiquement efficace d'un agent qui régule directement à la baisse une activité ou expression de RUNX1, traitant ainsi la malignité hématologique associée à l'activité ou à l'expression modifiée de RUNX1.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)
Licensing availability request The applicant has requested the International Bureau to indicate the availability for licensing purposes of the invention(s) claimed in this international application